Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and of HER2 (ErbB2) receptors. Lapatinib retained significant activity against HER2-amplified breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro and was synergistic in combination with trastuzumab in these cell lines.
300+Total Products
85+Oncology Products
115+Countrywith our customers
20Anti Virals
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.
Lapanix: Drug Registration Number: 341-335-010 Inclusion Date: 24-04-2018 Valid up to: 23-04-2023
+880-2-57165371
+880-2-57165379
